瘤分泌的细胞外囊泡通过触发炎性介质干细胞发育来抵消治疗反应
Crescenzo Massaro1,2, Hilal N Sensoy1, Manon Mulders1
1Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
概括
癌症细胞外囊泡 (EVs) 诱导炎症性介质干细胞 (iMSCs),在骨癌中驱动治疗阻力. 针对EV激活通路的组合疗法提供了一个有希望的策略来克服这种抵抗.
科学领域:
- 在瘤学瘤学.
- 干细胞生物学 干细胞生物学
- 癌症微环境 癌症微环境
背景情况:
- 治疗耐药性是骨癌治疗的一个重大挑战,经常受到瘤微环境的影响.
- 一种具有炎症特征 (iMSCs) 的间酶体干细胞的特定亚型已与治疗耐药性有关,但它们的起源和功能尚不清楚.
研究的目的:
- 研究癌症分泌的细胞外囊泡 (EVs) 在iMSCs的发展中的作用.
- 阐明EVs诱导iMSC并导致治疗耐药性的机制.
- 确定策略,以抵消骨癌中iMSC介导的耐药性.
主要方法:
- 用一种骨质肉瘤的正位异种移植小鼠模型来评估iMSCs在治疗耐药性的作用.
- 对EV改变的介质干细胞 (MSC) 进行了转录组分析,并与患者数据进行了比较.
- 功能测试确定了驱动iMSC开发的关键EV组件.
- 临床药物的有效性阻断iMSC诱导的耐药性被评估在体内.
主要成果:
- 癌症EVs诱导iMSCs的发展,这些iMSCs取消了TGFβ信号抑制的抗转移效应.
- 发电诱导的iMSC反映了骨髓瘤和多发性髓瘤患者活检中发现的 stromal 细胞的炎症特征.
- 癌症EVs激活不同的途径:与EV相关的TGFβ诱导IL6,而EV-RNA载荷增强TLR3介导的化学激素产生.
- 同时阻断EV激活通路的ladarixin和tocilizumab抑制转移并克服iMSC诱导的抵抗.
结论:
- iMSCs是骨癌中耐药性的关键驱动因素,由癌症EVs诱导.
- 细胞外囊泡被确定为iMSC发展的关键触发因素.
- 针对ladarixin和tocilizumab的组合治疗是一种有希望的策略,可以提高骨癌患者的治疗反应.
更多相关视频
相关概念视频
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Tumor Immunotherapy
497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


